|
**Overview**: Epstein-Barr Virus VCA Antibodies Panel**Introduction**: The Epstein-Barr Virus VCA Antibodies Panel is a diagnostic tool designed to screen for EBV infection using serum samples. In India, EBV seroprevalence is ~90 percent by adulthood, with VCA IgM indicating acute infection (infectious mononucleosis) and VCA IgG past exposure or reactivation. High burden in rural/low-SES children (IM-like illness) and immunocompromised (lymphoma, PTLD risk), underdiagnosis due to overlap with dengue/malaria. High morbidity from delayed diagnosis in transplant/HIV patients leading to complications. Per microbiology practices aligned with ICMR and Indian Society of Infectious Diseases guidelines, the test employs immunoassay for VCA IgG/IgM over 1-2 days with high specificity, valuable for acute vs past infection differentiation. This diagnostic falls under viral screening and targets patients with fever, lymphadenopathy, or immunocompromised status, addressing accurate detection to guide supportive care or antiviral. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing EBV-related complications. Its serum-based approach ensures reliable serology.**Other Names**: EBV VCA Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: VCA serology standard; in India, used in mononucleosis/TB differentials.**Purpose**: The test screens for 2 parameters including EBV VCA IgG to guide infection assessment, detect acute/past exposure, inform management.**Test Parameters**: 1. EBV VCA IgG, 2. EBV VCA IgM.**Pretest Condition**: No fasting required; patients should report fever, sore throat, lymphadenopathy.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on symptoms, duration, immunosuppression, transplant status.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated EBV including complications in immunocompromised, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or cross-reactivity can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive VCA IgM indicates acute infection; IgG past exposure, necessitating specialist input. Negative may require follow-up if suspicion high.**Specialist Consultation**: Infectious disease specialists should be consulted for management.**Additional Supporting Tests**: EBNA IgG, PCR for confirmation.**Test Limitations**: IgM may persist; comprehensive approach required.**References**: Indian Journal of Medical Microbiology 2024, EBV Studies India 2023. |
